Navigation Links
U.S. FDA Approves Bayer's Gadavist™ (Gadobutrol) Injection for MRI of the Central Nervous System
Date:3/14/2011

WAYNE, N.J., March 14, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has approved Gadavist™ (gadobutrol) Injection, a macrocyclic gadolinium-based contrast agent (GBCA), for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system (CNS).  

Gadavist is formulated at a higher concentration (1 mmol/mL) compared to certain other GBCAs.  Compared to 0.5 molar gadolinium-based contrast agents, the higher concentration of Gadavist results in half the volume of administration and a more compact contrast bolus.  It is important to closely examine the dosing table in the full prescribing information to determine the volume of Gadavist to be administered.

"The approval of Gadavist enriches our strong portfolio of MRI contrast media and provides a new option for U.S. healthcare providers in contrast-enhanced imaging of the CNS," said John Rotondo, Vice President, Commercial Operations, Bayer HealthCare Pharmaceuticals.  "Our MR contrast agents are some of the most widely used today, and Bayer is proud to be a world leader in diagnostic imaging."IMPORTANT SAFETY INFORMATIONWARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
  • Chronic, severe kidney disease (GFR < 30 mL/min/1.73m(squared)), or
  • Acute kidney i
    '/>"/>

    • SOURCE Bayer HealthCare Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... MOUNT PROSPECT, Ill. , May 21, 2013 /PRNewswire-USNewswire/ ... Domain (gTLD) approval process, the National Association of Boards ... own and operate the .PHARMACY domain suffix has passed ... initial evaluation. NABP intends to launch the .PHARMACY gTLD ... new domain available to legitimate online pharmacies and related ...
    (Date:5/21/2013)... Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: ... solution provider and operator of the largest network of ... parent of Chang,an Hospital, today reported its unaudited consolidated ... 2013 [1] . First Quarter 2013 Highlights ... revenues generated from the network business and hospital business, ...
    (Date:5/21/2013)... , May 21, 2013  NxStage Medical, Inc. (Nasdaq: ... dialysis products, today announced that it has entered into ... and in-center products to DaVita, the kidney care division ... ) For the use of products ... , NxStage has executed a second amended and ...
    Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13NxStage Announces New Agreements with DaVita 2
    ... 2012  Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company ... technologies in the field of transplantation therapy for patients ... technology from Yale University. "In the ... Herold and his colleagues at Yale University School of ...
    ... /PRNewswire-iReach/ -- PharmacyGPO, Inc.,  a ... the United States, today announced a three-year agreement ... (Photo: http://photos.prnewswire.com/prnh/20120507/CG01217 ) ... Smith, a leading national wholesaler, will be the ...
    Cached Medicine Technology:Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 3
    (Date:5/21/2013)... results from SOURCE XT one of the largest, ... reported today at EuroPCR 2013 show good clinical outcomes ... success for all access approaches, valve sizes and delivery ... 2688 consecutively enrolled patients (mean age 81.5 years) undergoing ... centres in 17 countries between July 2010 and October ...
    (Date:5/21/2013)... 2013, Paris, France: The Orsiro stent, which is ... biodegradable polymer, demonstrated non-inferiority to the Xience Prime ... in-stent late lumen loss at nine months in ... EuroPCR 2013 today. , The BIOFLOW-II substudy used ... to quantitatively assess neointimal hyperplasia and stent apposition ...
    (Date:5/21/2013)... 21, 2013 Arizona State University ... want to develop their ideas into solutions, products ... , The university is recruiting participants for AREA48 ... space” that provides early-stage entrepreneurs with opportunities to ... open to anyone, ASU is particularly seeking participation ...
    (Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...
    (Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
    Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
    ... guinea worm disease is almost eradicated from the planet earth. ... could be exterminated in a couple of years from now. ... ,Currently around 25,000 people in nine countries across the ... million people in twenty countries in the early 1980s. ...
    ... performance is reported to be the latest trend which is ... keen to learn and develop their skills to make sure ... interest of patients. ,More than 170 physician ... emergency care through the Physician Consortium for Performance Improvement organized ...
    ... cancers of the “triple negative” type are destructive and lethal, ... to a novel// study Published in the May 1, 2007 ... these tumors occur commonly among women who are African American ... the lower socioeconomic status (SES). The study also showed that ...
    ... children suffering ADHD are prone to alcohol addiction in ... suggesting that alcohol related problems could begin around the ... family stress appear to add to the risk of ... that children with attention deficit hyperactivity disorder (ADHD) are ...
    ... the incidence of chicken pox cases is on the rise. ... especially in the southern districts, are gearing up to tackle ... would be the first casualty if chicken pox is not ... cases have been already reported in a rather serious condition ...
    ... Going in for angioplasty? Pause for a moment. It has now ... arteries//. ,So much so, more than half a ... or premature angioplasty, suggests a new study. ,More important, ... heart patients, it says. ,Dr William Boden of ...
    Cached Medicine News:Health News:'Triple Negative' Breast Cancers Seem to Affect the Young, Minority 2Health News:ADHD Problem in Children – a Risk Factor for Alcohol Problems in Later Lif 2Health News:ADHD Problem in Children – a Risk Factor for Alcohol Problems in Later Lif 3
    Alphabetically organized monographs on more than 1,000 generic and 3,000 trade name drugs....
    ... Drug Companion is a comprehensive, authoritative ... 5,500 entries, with overdose management, Canadian ... This "Mini-Suite" of drug references and ... the PEPID Suites (ED, PRIMARY CARE ...
    ... Pocket Drug Guide 2005 includes over 1,000 ... relating to their selection and administration. Organized ... drug includes key data featuring common uses ... implications and patient education information. A list ...
    ... A to Z Drug Facts ... detailed information on thousands of medications. ... contraindications, side effect, drug interactions, patient ... ideal drug reference for physicians, students, ...
    Medicine Products: